Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when he plans for the next Adult Dental Health Survey to be published.
Answered by Steve Brine
No decisions have been taken yet on the funding or timing of the next Adult Dental Health Survey.
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment his Department has made of the utility of the information provided by the Adult Dental Health Survey in assessing and planning for oral health needs both nationally and locally.
Answered by Steve Brine
There has been no formal assessment of the use of previous Adult Dental Health Surveys. The comparable nature of the data facilitates the following uses: for national and local policy makers to design, implement and monitor policies on oral health and dental services; for dental commissioners in NHS England to ensure commissioned services are meeting the needs of the population; for local authorities to fulfil a statutory function to assess the oral health needs of their populations - to inform the adult oral health elements of their joint strategic needs assessments and their local adult oral health improvement plans.
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what estimate he has made of the number of people with learning disabilities accessing special care dentistry in England in the latest period for which figures are available.
Answered by David Mowat
Information is not held centrally on NHS England’s total spend on special care dentistry or the number of people with learning disabilities accessing special care dentistry.
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how much NHS England spent on special care dentistry in the most recent financial year for which figures are available.
Answered by David Mowat
Information is not held centrally on NHS England’s total spend on special care dentistry or the number of people with learning disabilities accessing special care dentistry.
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how much has been spent on external consultants at (a) Epsom Hospital, (b) East Surrey Hospital and (c) The Royal Surrey County Hospital respectively over the last five years.
Answered by Philip Dunne
The requested information is not held centrally.
The available information is provided in the table below.
The Department holds expenditure data for National Health Service trusts as part of the year end accounts consolidation process. The data is held for the trust which a hospital belongs to rather than for individual hospitals.
External Consultant Spend by Trust (2011/12-2015/16)
Financial Year | Epsom and St Helier University (£000) | Surrey and Sussex Healthcare NHS Trust (£000) | Royal Surrey County NHS Foundation Trust (£000) |
2011/12 | 2,836 | 881 | 2,067 |
2012/13 | 1,525 | 1,036 | 1,216 |
2013/14 | 1,289 | 509 | 2,288 |
2014/15 | 1,215 | 502 | 3,165 |
2015/16 | 1,784 | 56 | 2,537 |
Source: Department of Health Accounts and NHS Improvement
Notes:
1. This information is based on the Cabinet Office definition of “Consultancy Services” (https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/405538/6.1_Cons_definitions.pdf):
“Assistance provided by consultancy services provided outside the ’business-as-usual’ environment when in-house skills are not available and will be of no essential consequence and time-limited. Consultancy may include the identification of options with recommendations, or assistance with (but not delivery of) the implementation of solutions.”
This is not the same as spend on external medical consultants; which would have to be obtained from trusts/foundation trusts directly.
2. This guidance is issued to NHS trusts and NHS foundation trusts as part of the Department’s Group Accounting Manual, and can be seen on pages 160/161 of that document.
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment he has made of the adequacy of the funding provided by Health Education England for dental foundation training to facilitate access to the dental performers list; and if he will make a statement.
Answered by Philip Dunne
All graduates of United Kingdom dental schools secured a place on the dental foundation training scheme in 2014 and 2015. Information for 2016 will be made available by Health Education England once confirmed. Foundation Training requires selection on merit but this year, as in the last two years, the scheme rules prioritise applicants who have graduated from UK dental schools.
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what the cost to the public purse is of NHS psoriasis patients continuing their current treatment who do not reach the NICE goal of 75 per cent skin clearance from treatment start.
Answered by Jane Ellison
The National Institute for Health and Care Excellence (NICE) has approved a number of different treatments for psoriasis as part of its technology appraisal (TA) programme, the most recent of these being Secukinumab, which was recommended as a possible treatment for people with plaque psoriasis in July 2015. The National Health Service is legally obliged to fund medicines and treatments recommended by NICE's TA programme, meaning people can access these treatments wherever they live in the country.
Information regarding the cost to the NHS of the continued treatment of psoriasis patients who do not achieve 75% skin clearance is not collected. The NICE best practice guideline Psoriasis: assessment and management, published in October 2012, covers approaches to diagnosis and treatment and specialist referral. The majority of TA recommended psoriasis treatments are featured in the guideline, and their success in treating psoriasis is measured using Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. In most cases, NICE defines an adequate response to treatment as one that includes a 75% reduction in a PASI score. The NICE guidance can be found at the following link:
www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-35109629621701
For patients who do not responded adequately to either topical treatment or biological therapies, such as those recommended by the NICE TA programme, the guidance recommends referral to a specialised service. NHS England commissions specialised dermatology services nationally and has set out what providers must have in place in order to deliver specialised dermatology care, as well as defining referral criteria. For psoriasis patients, referrals are appropriate where their condition is severe and they have not responded to NICE approved biological therapies. More information on specialised dermatology services can be found at the following link:
www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps his Department is taking to ensure that patients with psoriasis are able to access the most effective NICE-approved treatment for their condition regardless of where they live in the country.
Answered by Jane Ellison
The National Institute for Health and Care Excellence (NICE) has approved a number of different treatments for psoriasis as part of its technology appraisal (TA) programme, the most recent of these being Secukinumab, which was recommended as a possible treatment for people with plaque psoriasis in July 2015. The National Health Service is legally obliged to fund medicines and treatments recommended by NICE's TA programme, meaning people can access these treatments wherever they live in the country.
Information regarding the cost to the NHS of the continued treatment of psoriasis patients who do not achieve 75% skin clearance is not collected. The NICE best practice guideline Psoriasis: assessment and management, published in October 2012, covers approaches to diagnosis and treatment and specialist referral. The majority of TA recommended psoriasis treatments are featured in the guideline, and their success in treating psoriasis is measured using Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage and plaque appearance. In most cases, NICE defines an adequate response to treatment as one that includes a 75% reduction in a PASI score. The NICE guidance can be found at the following link:
www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-35109629621701
For patients who do not responded adequately to either topical treatment or biological therapies, such as those recommended by the NICE TA programme, the guidance recommends referral to a specialised service. NHS England commissions specialised dermatology services nationally and has set out what providers must have in place in order to deliver specialised dermatology care, as well as defining referral criteria. For psoriasis patients, referrals are appropriate where their condition is severe and they have not responded to NICE approved biological therapies. More information on specialised dermatology services can be found at the following link:
www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps his Department is taking to support patients with hidradenitis suppurativa.
Answered by Jane Ellison
Hidradenitis suppurative (HS) affects around 90,000 people in England and can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin.
For those patients with the most serious forms of HS who cannot be managed through routine access treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with a involvement of a range of health and care professionals, subject to that patient’s needs. More information can be found at the following link:
www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf
The Department does not hold data on spending on individual dermatological conditions. However, the latest NHS Programme Budgeting data, which is for 2012-13, shows that the total spend on dermatology (excluding burns) was £1.98 billion.
Asked by: Paul Beresford (Conservative - Mole Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how much the treatment of hidradenitis suppurativa cost the NHS in England in (a) 2012, (b) 2013 and (c) 2014.
Answered by Jane Ellison
Hidradenitis suppurative (HS) affects around 90,000 people in England and can usually be managed with treatments including antibiotics, antiseptic washes and immunosuppressive treatments such as steroids or ciclosporin.
For those patients with the most serious forms of HS who cannot be managed through routine access treatments provided through primary or secondary care, a referral to a specialised dermatology service may be appropriate. NHS England commissions services for people with rare and complex skin conditions and has set out what providers must have in place in order to offer specialist dermatology care. These services may provide more intensive therapies with a involvement of a range of health and care professionals, subject to that patient’s needs. More information can be found at the following link:
www.england.nhs.uk/wp-content/uploads/2013/06/a12-spec-dermatology.pdf
The Department does not hold data on spending on individual dermatological conditions. However, the latest NHS Programme Budgeting data, which is for 2012-13, shows that the total spend on dermatology (excluding burns) was £1.98 billion.